A Phase 3 interventional study of efgartigimod PH20 SC in Generalized Myasthenia Gravis, sponsored by argenx. Completed at 47 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by argenx · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing efgartigimod alfa in Myasthenia Gravis — 11 open to participants now, 14 under way, 7 of them phase 3. efgartigimod alfa · Myasthenia Gravis.
Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, this one has the largest enrollment, is one of 4 that started in 2021, is one of 10 in phase 3, and was the 5th registered.
331 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.
Browse Myasthenia Gravis studies →11 of the 20 studies testing efgartigimod alfa in Myasthenia Gravis are open now, in 12 countries. Recruiting first, the newest first:
argenx · Sites in United States, Belgium, Germany and 5 more countries
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 65+
argenx · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 18+
Clinique Neuro-Outaouais · Sites in Canada
Ages 18–80
By country, each count listing its studies:
efgartigimod alfa: first FDA approval 2021 (VYVGART), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 12 · Phase 4 4
First in 2016; this study’s year is marked. 4 started in 2021.
This study's enrollment of 184 is above the median of 44 across 217 interventional studies indexed under Myasthenia Gravis.
Median enrollment 55 across the 20 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 8 most frequent:
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
18 studies in Myasthenia Gravis by argenx: 9 open now, 12 under way, 5 of them phase 3. Of 6 finished, 6 (100%) have results posted.
Among the 18 studies in Myasthenia Gravis by argenx, this one has the largest enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2021, is one of 7 in phase 3, and was the 5th registered.
argenx’s Myasthenia Gravis studies by the year they started, since 2016.
7 of the studies testing efgartigimod alfa in Myasthenia Gravis that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06765161Phase 3Clinique Neuro-OutaouaisEfgartigimod in IVIG Dependent Myasthenia Gravis Patients | 2027-01-06 |
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT07231523Phase 3Shanghai Zhongshan HospitalEFG vs IVIG in TAMG | 2027-06-01 |
| NCT06392386Phase 3argenxA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | 2027-09 |
| NCT06221501Shanghai Zhongshan HospitalPerioperative Efgartigimod for Thymoma and Myasthenia Gravis | 2026-12-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among argenx’s 18 in Myasthenia Gravis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety and tolerability of efgartigimod PH20 SC 1000 mg, and the clinical efficacy, PD, pharmacokinetics (PK), immunogenicity, impact on the quality of life (QoL) of the participants, treatment satisfaction, and administration method preference, and the feasibility of self- and caregiver-supported administration of the SC injection.
Treatment duration: 3-week treatment periods, repeated as needed with at least 28 days in between treatment periods
Health measurements: total levels of immunoglobulin G (IgG), Acetylcholine receptor binding autoantibodies (AChR-Ab) levels, Myasthenia Gravis Activities of Daly Living (MG-ADL).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies and:
Exclusion Criteria:
The participant was discontinued early from studies ARGX-113-2001 or ARGX-113-1705, unless the reason for discontinuation from study ARGX-113-1705 was to roll over into study ARGX-113-2002.
a. Participants who, in the investigator's judgment, are not benefiting from efgartigimod IV in study ARGX-113-1705 Part B are not eligible for roll over into ARGX-113-2002.
Has any of the following medical conditions:
History of unless deemed cured by adequate treatment with no evidence of reoccurrence for ≥3 years before the first administration of investigational medicinal product (IMP).
Participants with the following cancers can be included at any time:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receiving efgartigimod PH20 subcutaneous (SC) treatment
Biological: efgartigimod PH20 SC
Drug pages: Efgartigimod alfa · Hyaluronidase (human recombinant)
Subcutaneous injection with efgartigimod PH20 SC
Number of AEs, SAEs and AESIs
Adverse events, Serious Adverse event and Adverse events of special interest. Adverse events in the 'Infections and infestations' SOC were defined as AESIs because efgartigimod causes a transient reduction in total IgG levels.
Time frame: Up to 3.5 years
MG-ADL Total Score Changes From Baseline
The Myasthenia Gravis Activities of Daily Living (MG-ADL) is an 8-item patient-reported scale that assesses MG symptoms and their effects on daily activities. It evaluates a participant's capacity to perform different activities in their daily life. The total score ranges from 0 to 24 with higher scores indicating more impairment.
Time frame: Up to week 4 of the first cycle
Percent Change in Total IgG Levels From Baseline
IgG: immunoglobulin G
Time frame: Up to week 4 of the first cycle
Percent Change in AChR-Ab From Baseline in AChR-Ab Seropositive Participants
AchR-Ab: anti-acetylcholine receptor antibodies.
Time frame: Up to week 4 of the first cycle
Efgartigimod Serum Concentrations
Time frame: Up to week 4 of the first cycle
Incidence of ADAs Against Efgartigimod Over Time
ADA: Anti-drug antibodies.
Time frame: Up to 3.5 years
Incidence of NAbs Against Efgartigimod Over Time
NAbs: neutralizing antibodies
Time frame: Up to 3.5 years
Incidence of Antibodies Against rHuPH20 Over Time
Time frame: Up to 3.5 years
Incidence of NAbs Against rHuPH20 Over Time
NAbs: neutralizing antibodies
Time frame: Up to 3.5 years
Changes in Total MG-QoL15r From Baseline
Myasthenia Gravis Quality of Life 15 item scale revised (MG-QoL 15r) scores range from 0 to 30 with a higher score representing more severe symptoms.
Time frame: Up to week 4 of the first cycle
Changes in EQ-5D-5L VAS Score From Baseline
EuroQoL 5 Dimensions 5-Level (EQ-5D-5L) visual analog scale (VAS) scores range from 0 to 100 with a higher score representing better health.
Time frame: Up to week 4 of the first cycle
Percent of Participants or Caregivers by Number of Training Visits Needed to be Competent to Start Self- or Caregiver-Supported Administration
Time frame: Up to 3.5 years
Percent of Self- or Caregiver-supported Study Drug Administration Among All Study Treatment Visits at Home
Time frame: Up to 3.5 years
This study was conducted at 47 sites that enrolled participants in 12 countries. A total of 184 participants rolled over from ARGX-113-2001 and ARGX-113-1705, of whom 180 participants were exposed to efgartigimod PH20 SC treatment.
| Milestone | Efgartigimod PH20 SC |
|---|---|
| Started | 180 |
| Completed | 138 |
| Not completed | 42 |
| Withdrew: Withdrawal by subject | 16 |
| Withdrew: Adverse event | 5 |
| Withdrew: Lack of efficacy | 5 |
| Withdrew: Death | 4 |
| Withdrew: Physician decision | 4 |
| Withdrew: Requires prohibited medication | 4 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Approved drug available for indication | 1 |
| Withdrew: Sponsor request | 1 |
Adverse events, Serious Adverse event and Adverse events of special interest. Adverse events in the 'Infections and infestations' SOC were defined as AESIs because efgartigimod causes a transient reduction in total IgG levels.
| events | Efgartigimod PH20 SC |
|---|---|
| Number of AEs | 3325 |
| Number of SAEs | 107 |
| Number of AESIs | 420 |
The Myasthenia Gravis Activities of Daily Living (MG-ADL) is an 8-item patient-reported scale that assesses MG symptoms and their effects on daily activities. It evaluates a participant's capacity to perform different activities in their daily life. The total score ranges from 0 to 24 with higher scores indicating more impairment.
| score on a scale | Efgartigimod PH20 SC |
|---|---|
| Cycle 1, Week 1 | -2.2 ± 0.20 |
| Cycle 1, Week 2 | -3.4 ± 0.21 |
| Cycle 1, Week 3 | -3.9 ± 0.22 |
| Cycle 1, Week 4 | -4.0 ± 0.23 |
IgG: immunoglobulin G
| Percent change | Efgartigimod PH20 SC |
|---|---|
| Percent Change in Total IgG Levels From Baseline | -62.6 ± 0.93 |
AchR-Ab: anti-acetylcholine receptor antibodies.
| Percent change | Efgartigimod PH20 SC |
|---|---|
| Percent Change in AChR-Ab From Baseline in AChR-Ab Seropositive Participants | -57.6 ± 2.29 |
| ng/mL | Efgartigimod PH20 SC |
|---|---|
| Efgartigimod Serum Concentrations | 21693 ± 8242 |
ADA: Anti-drug antibodies.
| Participants | Efgartigimod PH20 SC |
|---|---|
| Incidence of ADAs Against Efgartigimod Over Time | 35 |
NAbs: neutralizing antibodies
| Participants | Efgartigimod PH20 SC |
|---|---|
| Incidence of NAbs Against Efgartigimod Over Time | 11 |
| Participants | Efgartigimod PH20 SC |
|---|---|
| Incidence of Antibodies Against rHuPH20 Over Time | 49 |
NAbs: neutralizing antibodies
| Participants | Efgartigimod PH20 SC |
|---|---|
| Incidence of NAbs Against rHuPH20 Over Time | 1 |
Myasthenia Gravis Quality of Life 15 item scale revised (MG-QoL 15r) scores range from 0 to 30 with a higher score representing more severe symptoms.
| score on a scale | Efgartigimod PH20 SC |
|---|---|
| Cycle 1, Week 1 | -2.5 ± 0.29 |
| Cycle 1, Week 2 | -3.7 ± 0.34 |
| Cycle 1, Week 3 | -4.5 ± 0.38 |
| Cycle 1, Week 4 | -4.7 ± 0.39 |
EuroQoL 5 Dimensions 5-Level (EQ-5D-5L) visual analog scale (VAS) scores range from 0 to 100 with a higher score representing better health.
| score on a scale | Efgartigimod PH20 SC |
|---|---|
| Changes in EQ-5D-5L VAS Score From Baseline | 13.9 ± 1.32 |
| Percent of participants | Efgartigimod PH20 SC |
|---|---|
| 0 visits | 4.8 |
| 1 visit | 45.8 |
| 2 visits | 13.9 |
| 3 visits | 11.4 |
| 4 visits | 12.7 |
| 5 visits | 1.8 |
| 6 visits | 5.4 |
| 9 visits | 1.2 |
| 11 visits | 0.6 |
| 12 visits | 0.6 |
| 22 visits | 0.6 |
| 37 visits | 0.6 |
| 42 visits | 0.6 |
| Percent | Efgartigimod PH20 SC |
|---|---|
| Percent of Self- or Caregiver-supported Study Drug Administration Among All Study Treatment Visits at Home | 49.2 |
Collected over 3.5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Efgartigimod PH20 SC | 5/180 (2.8%) | 55/180 (30.6%) | 167/180 (92.8%) |
| Event | Efgartigimod PH20 SC |
|---|---|
| Myasthenia gravisNervous system disorders | 11/180 |
| PneumoniaInfections and infestations | 7/180 |
| COVID-19Infections and infestations | 4/180 |
| Myasthenia gravis crisisNervous system disorders | 4/180 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 4/180 |
| Angina unstableCardiac disorders | 2/180 |
| Cardiac failure congestiveCardiac disorders | 2/180 |
| CellulitisInfections and infestations | 2/180 |
| SepsisInfections and infestations | 2/180 |
| Rib fractureInjury, poisoning and procedural complications | 2/180 |
| Event | Efgartigimod PH20 SC |
|---|---|
| Injection site erythemaGeneral disorders | 55/180 |
| COVID-19Infections and infestations | 52/180 |
| HeadacheNervous system disorders | 48/180 |
| NasopharyngitisInfections and infestations | 36/180 |
| DiarrhoeaGastrointestinal disorders | 32/180 |
| Upper respiratory tract infectionInfections and infestations | 32/180 |
| Injection site bruisingGeneral disorders | 24/180 |
| Injection site painGeneral disorders | 22/180 |
| Back painMusculoskeletal and connective tissue disorders | 22/180 |
| Injection site pruritusGeneral disorders | 21/180 |
| Age, Categorical(Participants) | Efgartigimod PH20 SC |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 139 |
| >=65 years | 41 |
| Age, Continuous(years) | Efgartigimod PH20 SC |
|---|---|
| Mean | 50.8 ± 15.50 |
| Sex: Female, Male(Participants) | Efgartigimod PH20 SC |
|---|---|
| Female | 119 |
| Male | 61 |
| Race/Ethnicity, Customized(Participants) | Efgartigimod PH20 SC |
|---|---|
| Asian | 16 |
| Black or African American | 2 |
| White | 161 |
| Multiple | 1 |
| Race/Ethnicity, Customized(Participants) | Efgartigimod PH20 SC |
|---|---|
| Hispanic or Latino | 8 |
| Not Hispanic or Latino | 172 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Apr 2021 to primary completion in Dec 2024, 44 months.
Results were first posted in Jan 2026, 1 year after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 44 months is above that.
Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Efgartigimod alfa · Hyaluronidase (human recombinant)